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Abstract: The complex neurodevelopmental disorder schizophrenia is thought to be induced by an interaction between 
predisposing genes and environmental stressors. In order to get a better insight into the aetiology of this complex disorder, 
animal models have been developed. In this review, we summarize mRNA expression profiling studies on neurodevelop-
mental, pharmacological and genetic animal models for schizophrenia. We discuss parallels and contradictions among 
these studies, and propose strategies for future research. 
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INTRODUCTION 
  Schizophrenia is a complex psychiatric disorder with a 
lifetime risk of ~1%. The first symptoms usually manifest 
during late adolescence or early adulthood, but the origin of 
the disorder is thought to be neurodevelopmental [1, 2]. The 
disorder is characterized by delusions, hallucinations, disor-
ganized speech, grossly disorganized or catatonic behaviour, 
and negative symptoms [3]. Negative symptoms concern the 
absence of or reduction in basic emotional and behavioural 
processes and include e.g. flat or blunted emotions, poverty 
of speech, the inability to experience pleasure, and lack of 
motivation. Although at present not considered a diagnostic 
criterion, many patients suffer from cognitive impairments 
such as problems with attention, concentration, learning, 
memory and abstract thinking [4, 5]. Environmental factors 
in combination with predisposing genes appear to be impor-
tant for the aetiology of schizophrenia. Environmental fac-
tors include prenatal infections, maternal malnutrition during 
pregnancy, obstetric complications, poverty, child abuse and 
neglect, war trauma, loss of parent and migration [5-8]. Such 
factors may affect gene expression by epigenetic mecha-
nisms [9, 10]. Family, twin and adoption studies have shown 
that schizophrenia is a disorder with a substantial genetic 
contribution [11, 12]. On the basis of linkage analyses, loci 
on 21 of the 23 chromosomes have been linked to the disor-
der. A meta-analysis has revealed that in various populations 
chromosomal region 2q, but also 1q, 8p, 22q and other   
loci, are associated with susceptibility to schizophrenia   
[13]. Follow-up studies on the regions implicated by the ge-
nome scans have resulted in positional candidate genes such 
as neuregulin-1 (NRG1; 8p12) and catechol-O-methyl- 
transferase (COMT; 22q11.21) [14]. However, the final   
outcome of genetic research on schizophrenia is at present 
unclear, the search for vulnerability genes for schizophrenia 
has not resulted in consistent findings, and many genes   
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associated with psychiatric disorders have only a small effect 
and are mostly linked to more than one disorder [15]. The 
inconsistent results may arise from the clinical heterogeneity 
displayed by these disorders [16]. The debate continues on 
whether in the fifth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-V) schizophrenia should 
be considered as a single disorder or as a group of several 
disease entities [17]. 
  In order to get a better insight into the function of candi-
date genes and the aetiology of the disorder in general,   
multiple animal models have been developed. A problem 
encountered here is that the most prominent symptoms of 
schizophrenia - delusions, hallucinations and thought disor-
der - can not be reproduced in rodents and even not in non-
human primates. Furthermore, a well-established genotype, 
cellular phenotype or other biological marker that is charac-
teristic for the disorder is not available for validation of a 
model. Nevertheless, a number of symptoms such as e.g. 
behaviours related to increased dopaminergic transmission 
(dopamimetric-induced hyperlocomotion), social withdrawal 
(reduced contact with unfamiliar partners), loss of prepulse 
inhibition (PPI, a symptom at the interface of psychosis and 
cognition) and cognitive deficits (impaired performance in a 
spatial memory test) have been observed in animal models 
[18, 19]. It is therefore generally acknowledged that animal 
models may provide new insights into the pathophysiology 
and aetiology of schizophrenia [18]. In general and based   
on the way they have been created, animal models can be 
divided into three groups: (1) neurodevelopmental models, 
(2) pharmacological models and (3) genetic models. Such 
animal models for schizophrenia and their characteristics 
have been described in many excellent papers and reviews 
[20-22]. This review focuses on microarray mRNA expres-
sion data obtained from the schizophrenia animal models 
(Table 1). 
mRNA EXPRESSION PROFILING IN NEURODE-
VELOPMENTAL ANIMAL MODELS 
  To generate a neurodevelopmental animal model for 
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Table 1. An Overview of Schizophrenia Animal Models Used in Microarray Studies 
Animal Model  Approach  Number of Gene(s) with Affected mRNA Expression  Ref. 
C57BL6J mice infected with 
H1N1 influenza virus on  
pregnancy day 18 
Mouse genome 430 2.0 array  
(Affymetrix) covering >39000 transcripts 
Hippocampus: 175 (PND0), 21 (PND14) and 62 (PND56) 
Cerebellum: 157 (PND0), 16 (PND14) and 96 (PND56) 
Prefrontal cortex: 72 (PND0), 33 (PND14) and 110 (PND56) 
[26] 
Balb/c mice infected with  
H1N1 influenza virus on  
pregnancy day 9 
Murine 430 high-density oligonucleotide 
array (Affymetrix) covering ~20000 
mouse genes and ESTs 
Whole brain: 39 genes  [30] 
Lewis rat pups inoculated with 
NBD within 12 hours of birth, 
sacrificed at 4 weeks of age 
3DNA Array 350 Expression Array  
(Genisphere) covering 8064 genes 
Cerebellum: MT-I/-II (Mt1a) 9.09 fold increase 
Hippocampus: MT-I/-II (Mt1a) 2.95 fold increase 
[32] 
Pregnant Sprague-Dawley rats 
subjected to a repeated variable 
stress paradigm from ED14  
to ED22, male pups were  
subjected to acute stress  
at PND56 and sacrificed 
Affymetrix RG U34A microarray  
covering 8799 genes 
Frontal pole: 35 genes  [34] 
VH-lesioned Fisher 344 (F344) 
rats, daily i.p. haloperidol  
treatment for 14 days  
starting at PND55 
GeneFilter® DNA microarray blots  
(Research Genetics Inc., Huntsville)  
covering 37575 cDNA clones 
VH-lesioned F344 versus sham-lesioned F344 rats - Frontal 
tissue: 828 genes Temporal tissue: 768 genes 
Haloperidol treated versus control VH-lesioned F344 -  
Frontal tissue: 404 genes- Temporal tissue: 595 genes 
[37] 
New born F344 rats separated 
from their dams for 8 hours every 
other day (PND2 to 10)  
Affymetrix rat U34A microarray   Hippocampal slices: 24 genes including  
Ttr (4.85 fold decrease) 
[39] 
Institute for Cancer Research 
(ICR) Mice subjected to isolated 
rearing for 4 weeks 
GeneChip mouse genome 430 2.0 Array 
(Affymetrix) covering 45101 probe sets 
Dentate gyrus: 22 genes including Nr4a2/Nurr1 and Npas4 [42] 
ICR mice, daily i.p.  
PCP for 24 days 
Clontech Atlas glass array mouse 1.0 
covering 1000 cDNAs 
Cerebral cortical tissue: 73 genes  [45] 
Male Sprague-Dawley rats  
injected once with PCP sacrificed 
4 hours after injection 
Affymetrix rat U34A microarray  
covering 8784 probe sets 
Prefrontal cortex: 477 genes  [46] 
Male Wistar rats injected  
with PCP at PND8 or PND50  
and sacrificed 60-90 minutes 
after injection 
Affymetrix rat genome 230 2.0 array  
covering over 30000 transcripts 
Thalamus: c-fos, Klf2, Nr4a3, Klf4 and leiomodin2 
(Lmod2)-like 
[47] 
Sprague-Dawley rats with a  
spinal cord (segment T8) injury 
administered with MK-801 one 
hour before and after the injury 
Affymetrix Rat Neurobiology U34  
oligonucleotide microarray containing  
1322 probes 
combined T7,T8 and T9 spinal cord segments: 168 genes  
that were not affected by spinal cord injury itself 
[59] 
B6C3F1 mice treated with a 
single i.p. s(+)ketamine injection 
anaesthetized and sacrificed 30 
minutes post injection 
Affymetrix MGU-74 av2 GeneChips® 
covering 12488 genes 
Hippocampus/amygdala/ 
hypothalamus: 50 genes 
[49] 
Male Wistar rats (injected with 
MK-801) were subjected to 
ischemic preconditioning (IPC) 
by sublethal bilateral carotid 
artery occlusion (BCAO) and 3 
days later to lethal BCAO 
Affymetrix RG 230 2.0 array covering 
31020 probe sets 
Hippocampus: 1893 genes  [60] 
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Table 1. contd…. 
Animal Model  Approach  Number of Gene(s) with Affected mRNA Expression  Ref. 
Male Wistar rats i.p. injected with 
MK-801 or memantine narcotized 
with CO2 and sacrificed 4 hours 
post injection 
Rat 1.0 Atlas Glass Microarrays  
(Clontech) containing 86 controls  
and 1090 well characterized 
transcripts  
Posterior cingulate and anterior retrosplenial cortices: 
MK-801: 34 genes 
Memantine: 28 genes 
[61] 
Male Wistar rats i.p. injected  
with (+)-MK801 maleate daily 
for 14 days, tested for social 
interaction and sacrificed  
on day of last injection 
GeneChip® Rat Expression 230A array 
(Affymetrix) containing 15923 probe sets 
Amygdala: 39 genes including AVP and Ttr [62] 
APO-SUS versus APO-UNSUS 
Wistar rats 
Rat NeuroGEM 2.02 microarrays  
containing 8478 Sprague Dawley rat  
nervous system cDNAs 
Hippocampus: 1 gene, Aph-1b  [40] 
Male Sprague–Dawley albino  
rats administered i.p. daily  
with olanzapine and sacrificed  
24 h after the last injection  
under deep anaesthesia 
Affymetrix rat genome 230 2.0  
array set containing ~28000  
rat genes and ESTs 
Frontal cortex: 69 genes  [69] 
Male C57BL/6 mice i.p. injected 
with haloperidol, olanzapine,  
or clozapine daily for 7 days  
and sacrificed under 4%  
halothane anaesthesia  
five hours post injection 
Affymetrix GeneChip Mouse Genome  
430 2.0 microarrays containing  
over 39000 transcripts 
Whole brain:11941 transcripts by one or  
more drugs, 249 transcripts by all 3 drugs 
[70] 
Male Wistar rats injected i.p.  
with clozapine and sacrificed  
1, 6 or 24 hrs post injection 
Atlas Rat 1.2 Array filter (Clontech)  
covering 1176 sequence-verified cDNAs 
Anterior cingulate and prefrontal cortices:  
217 genes including 22 genes with  
a presynaptic function 
[76] 
ICR mice injected subcutaneous 
with clozapine daily for  
20 days and sacrificed  
20 hours post injection 
Atlas Rat 1.2 Array filter (Clontech)  
covering 1176 sequence-verified cDNAs 
Cerebral cortical tissues: undefined number of  
genes including potassium channel, prostaglandin  
D2 synthase, serotonin receptor type 2 and 
myelin-associated oligodendrocytic basic protein  
[80] 
C57BL6 mice received daily for 
31 days haloperidol or clozapine  
or phenylpropanolamine  
via food pellets 
Murine Genome U74A Array  
(Affymetrix) containing ~12000 genes 
Cortex: 1156 transcripts in one or more models  [81] 
Sprague–Dawley rats injected i.p. 
daily with Haloperidol or 
Risperidone and sacrificed 96 
hours (acute treatment) or 4 
weeks (chronic treatment) after  
initiation of drug treatment. 
PXM oligo-nucleotide slides  
(Full Moon Biosystems) containing  
8000 rat gene-specific,  
amino-modified oligonucleotides 
Prefrontal/fronto-parieto-temporal cortices: Haloperidol:- 
acute: 28 genes 
- chronic: 9 genes 
Risperidone: 
- acute: 89 genes 
- chronic: 17 genes 
[84] 
Male Sprague-Dawley rats  
injected i.p. with risperidone 
daily for 4 weeks and sacrificed 
under CO2 anesthesia  
24 hours post injection 
GeneMap Rat Clone Arrays  
(Genomic Solutions Inc.)  
containing cDNA fragments  
covering 1536 genes 
Frontal cortex: 17 genes  [85] 
Nurr1 KO mice generated by 
mating of Nurr1 +/- animals. 
Pregnant females were sacrificed 
at ED12.5 and Nurr1 KO  
embryos selected 
Affymetrix MGU74Av2 and MGU74Bv2 
gene chips covering  
Ventral Midbrain: 
Undefined small number of genes including GTPCH 
[92] 
Reeler mouse at ED11.5  Qiagen 70mer oligo chip  Brain: 1 gene, mouse Strawberry Notch 1 mSno1 [98] 
Ten weeks old DfI/+ mice  Agilent Oligo Mouse Microarrays  
containing 60-mer oligonucleotide  
probes for 20915 murine genes 
Hippocampal dentate granule neurons: 13 genes   [100] Gene Expression Profiling in Rodent Models for Schizophrenia  Current Neuropharmacology, 2010, Vol. 8, No. 4    385 
 
infection are employed and since they should affect brain 
development the factors are applied to animals prenatally (or 
at a young age). Epidemiologic evidence has suggested that 
maternal infection by a virus may lead to the genesis of 
schizophrenia [23, 24]. In mice, prenatal influenza infection 
causes effects on brain structure and function such as in-
creased serotonin levels [25]. To establish a schizophrenia 
animal model, C57BL6J mice have been infected on preg-
nancy day 18 with H1N1 influenza virus. This resulted in a 
moderate, sublethal infection with a mean virus titer of 10
5.25 
cell culture infectious dose (CCID)50/ml [26]. Brain tissues 
from the offspring of these mice were collected for mRNA 
expression profiling at post natal day (PND) 0, 14 (child-
hood) and 56 (adulthood). Analysis with the mouse genome 
430 2.0 array (Affymetrix) showed that in the brains of the 
prenatally exposed mice compared to the brains of control 
offspring the highest number of genes were up- or down-
regulated at PND 0 (72, 175 and 157 genes in frontal, hippo-
campal and cerebellar brain areas, respectively) and PND 56 
(110, 62 and 96 genes, respectively), relative to PND 14 (33, 
21 and 16, respectively). A number of genes was validated 
by quantitative polymerase chain reaction (qPCR), including 
v-erb-B2 avian erythroblastic leukaemia viral oncogene 
(Erbb4), semaphorin 3A (Sema3a), very-low density lipopro-
tein receptor (Vldlr), and ATPase,Na+/K+ transporting, beta 
2 polypeptide (Atp1b2) [26]. These genes had been impli-
cated previously in the aetiopathology of schizophrenia [27-
29]. Compared to viral infection in Balb/c mice at pregnancy 
day 9 [30], more and other genes were differentially ex-
pressed in the offspring of mice infected at pregnancy day 18 
[26]. One of the genes differentially expressed in the off-
spring of mice infected at either pregnancy day 9 or day 18 
was  forkhead box P2 ( Foxp2) [26, 30]. Foxp2 polymor-
phisms have been linked to schizophrenic patients with audi-
tory hallucinations [31]. Another viral infection in rats, Neo-
natal Borna disease (NBD) virus infection, results in life-
long viral persistence and causes behavioural and neurode-
velopmental abnormalities. In the hippocampus and cerebel-
lum of 4-weeks old Lewis rats that within 12 hours of birth 
had been inoculated into the right cerebral hemisphere with 
NBD, gene expression has been analysed with an 8K oli-
gonucleotide array. The expression of metallothionein 1a 
(Mt1a or MT-I/-II) was increased ~9- and ~3-fold in the 
cerebellum and hippocampus, respectively. Furthermore, the 
expression of Mt3 was increased in astrocytes and of solute 
carrier family 30 (zinc transporter) member 3 (Slc30a3/ZnT-
3) was decreased in the hippocampus. The alterations in 
ZnT-3 expression, and astrocytic Mt1a and Mt3 induction, in 
combination with previously described changes in the ex-
pression of cytokine- and apoptosis-related products in NBD 
rats, suggest a multifactorial pathway leading to selective 
damage [32]. 
  Another environmental factor that has been implicated in 
the aetiology of schizophrenia is prenatal stress [33]. To cre-
ate an animal model, repeated variable stress paradigms have 
been applied to pregnant Sprague–Dawley rats during the 
last week of gestation. A microarray analysis of the frontal 
pole brain area of the prenatally stressed adult offspring and 
non-stressed adult controls revealed significant changes in 35 
genes. Three differentially expressed genes encoded neuro-
transmitter receptor subunits or associated proteins, two were 
involved in calcium/calmodulin signaling, two were associ-
ated with neurotransmitter vesicles or vesicle recycling and 
two were Na
+/K
+-transporting ATPases [34]. Both the neu-
rodevelopmental animal model based on prenatal influenza 
infection [26] and the model generated by prenatal stress 
[34] displayed differential expression of Na
+/K
+-ATPase 
genes and potassium voltage-gated channel genes. However, 
the majority of the differentially expressed genes was differ-
entially expressed in only a single animal model.  
  A third neurodevelopmental animal model constitutes the 
neonatal ventral-hippocampal (VH) lesion rat model that 
exhibits many of the behavioural features of pharmacological 
schizophrenia models [18, 35, 36]. The locomotor abnor-
malities induced by the VH lesions differ between rat strains 
and therefore transcript expression was compared between 
saline- or haloperidol-treated adult VH-lesioned Fischer-344 
and Lewis rats [37]. Three variables were compared, namely 
with respect to strain (Fischer-344 versus Lewis), to age (day 
6 versus day 70) and to treatment (saline versus haloperidol), 
and suppression subtraction hybridization was used to iden-
tify changes in transcript levels. Genes differentially ex-
pressed in all three cases included mitochondrial cytochrome 
oxidase (complex IV) subunits including COX1 and 2, mito-
chondrial tRNA, g and z isoforms of 14-3-3, adenosine mo-
nophosphate deaminase 3 (Ampd3), and a 25-kD synaptoso-
mal associated protein (SNAP-25) [37].  
  A further neurodevelopmental animal model concerns the 
maternal deprivation rat model. Maltreatment, such as abuse 
and neglect, is a susceptibility factor for psychiatric disorders 
[38]. Fisher 344 rat pups were separated for 8 hours from 
their mother every other day between PND 2 and 10. At the 
age of 13 weeks, the rats were sacrificed and gene expression 
in hippocampal slices was analysed with an U34A (Af-
fymetrix) array. The expression of fifteen genes was upregu-
lated and of nine genes downregulated. The most prominent 
change in expression was found for the transthyretin (Ttr) 
gene. In the brain the expression of this gene is nearly re-
stricted to the choroid plexus and therefore the authors 
speculated about a possible function for the choroid plexus in 
stress [39]. However, in other studies the differential expres-
sion of Ttr was considered to be the result of a tissue-
isolation artefact (contaminating choroid plexus) rather than 
being a differentially expressed gene of interest [40].  
  Yet another example of a neurodevelopmental animal 
model are three-weeks old, weaned Institute for Cancer Re-
search mice that were isolated for 3 days, 2 weeks or 4 
weeks, a treatment that may also affect brain development 
[41]. In these mice, mRNA expression in the dentate gyrus 
was analysed with a GeneChip mouse genome 430 2.0 array 
(Affymetrix), but no obvious changes were found. However, 
using a general linear model incorporating the feeding period 
the downregulation of two genes was observed, namely of 
nuclear receptor subfamily 4, group A, member 2 (Nr4a2/ 
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mRNA EXPRESSION PROFILING IN PHARMA-
COLOGICAL ANIMAL MODELS 
  The neuropharmacological animal models for schizo-
phrenia are based on specific neurotransmitter systems   
(typically dopamine (DA) and glutamate). Psychotomimetic 
substances (DA agonists, N-methyl-D-aspartate (NMDA) 
antagonists) have been used to generate schizophrenia-like 
symptoms in animals. In rodents, phencyclidine (PCP) and 
other antagonists of the NMDA-type glutamate receptor pro-
duce positive and negative symptoms, and cognitive distur-
bances remarkably similar to those observed in schizophre-
nia patients [43]. Animals in which these symptoms were 
induced by PCP or related compounds have therefore been 
considered to represent useful pharmacological models for 
this complex disorder. A single administration of PCP during 
the late foetal or early postnatal period in rats (corresponding 
to the third trimester of human pregnancy) produced behav-
ioral symptoms indicative of NMDA receptor blockade last-
ing for 8 to 10 hours and resulted in increased neuronal death 
by apoptosis [44]. Acute and chronic prenatal or neonatal 
administration of PCP to rats led to changes in behaviour of 
the adult animal, such as hyperlocomotion, impairments in 
information processing and increased stereotypic behaviour, 
and changes in the glutamatergic, dopaminergic and 
GABAergic systems [reviewed in 43]. The influence of PCP 
administration on mRNA expression levels has been reported 
already in 2002. Applying a Clontech Atlas glass mouse 1.0 
arrays, 28 genes have been found to be upregulated (includ-
ing tyrosine 3-hydroxylase, Th) and 45 genes were down-
regulated (including voltage-gated potassium channel, 
subfamily H (eag-related), member 1, Kcnh1) in mice 
injected with PCP once a day for 24 days [45]. Using newer 
microarrays representing more genes and following acute 
PCP treatment, mRNA expression changes in 477 genes 
have been observed in adult rat prefrontal cortex (PFC), a 
brain area associated with cognitive dysfunction in 
schizophrenia. One of the downregulated genes was voltage-
gated K
+ channel Kcna4 [46], yet another potassium voltage-
gated channel gene differentially expressed in an animal 
model for schizophrenia. The observed upregulation of c-fos, 
Klf2,  Nr4a3,  Klf4 has been confirmed in an independent 
study that also reported the upregulation of Leiomodin 2 
(Lmod2) in the thalamus of male rats following acute PCP 
administration at PND 50 but not at PND 8, suggesting that 
Lmod2 may be involved in the age-dependent onset of drug-
induced schizophrenia-like psychosis [47]. 
  Another antagonist of the NMDA receptor is ketamine, a 
PCP derivative [48]. In the to our knowledge only report on 
the genome-wide analysis of mRNA expression following 
ketamine administration, 50 genes have been found to be 
differentially expressed in the combined hippocampus, 
amygdala and hypothalamus regions of singly injected mice 
[49]. A number of the differentially expressed genes is asso-
ciated with tissue/organ/system development, such as gastru-
lation brain homeobox 2 (GBX2) and early growth response 
2 (EGR2)  [50, 51],  or cancer/apoptosis, such as protein 
kinase C delta (PRKCD), secreted phosphoprotein 1 (SPP1/ 
OPN), prostaglandin-endoperoxide synthase 2 (Ptgs2;  also 
named cyclo-oxygenase 2, COX-2) and growth arrest and 
DNA-damage-inducible 45 gamma (GADD45g) [52-55]. 
The investigators followed up on Troponin T1 (Tnnt1) since 
this gene showed consistently strongly (2- to 4-fold) elevated 
expression in the brains of treated mice and was found to be 
exclusively regulated by FoxO1, a gene thought to be in-
volved in metabolic pathways and energy homeostasis [49]. 
The activation of FoxO1 in the hypothalamus of normal mice 
increases food intake and body weight, whereas its inhibition 
decreases both processes, suggesting that FoxO1 indeed 
plays a role in central energy homeostasis and hunger/ 
appetite behaviours [56]. Weight gain and abdominal adipos-
ity may be central to the pathophysiology of the metabolic 
syndrome observed among neuropsychiatric patients [57], 
and  Tnnt1 may be the link between ketamine and weight 
gain [49].  
  A further antagonist of the NMDA receptor is MK-801 or 
dizocilpine [58]. The effect of MK-801 on mRNA expres-
sion levels following spinal cord injury (SCI) has already 
been analysed in 2002 [59]. Although SCI is not linked to 
schizophrenia, it is still of interest to compare the effects of 
the NMDA receptor antagonists PCP, ketamine, and MK-
801 following SCI. One hour after traumatizing adult male 
Sprague-Dawley rats, the mRNA levels of 165 genes and 
expressed sequence tags (ESTs) were changed on rat neuro-
biology U34 microarrays (Affymetrix). The affected mRNA 
levels were mostly of genes that are involved in transcrip-
tion, inflammation, cell survival and membrane excitability. 
Intrathecal administration of MK-801 directly to the injury 
site at 1 hour before the injury and at 1 hour after the injury 
reversed the effect of SCI on the expression levels of about 
half of the SCI-affected mRNAs. Additionally, MK-801 
treatment changed the mRNA levels of 168 genes and ESTs 
that had not been affected by SCI [59]. In another study, 
ischemic insults were induced in fasted male Wistar rats and 
hippocampal mRNA levels were analysed with an Af-
fymetrix Rat Genome 230 2.0 array (31020 probe sets). Di-
rectly following the lethal ischemic insult 967 genes were 
upregulated in vehicle/IPC versus MK-801/IPC rat brains, 
while 926 genes were downregulated. The investigators fur-
ther investigated the downregulation of COX-2 (Ptgs2) and 
confirmed by Western blot analysis that at 24 h following 
lethal ischemia the expression of COX-2/Ptgs2 was substan-
tially reduced in the vehicle/IPC group in comparison to the 
vehicle/sham (non-preconditioned) and MK801/IPC groups 
[60]. Thus, in this study MK-801 treatment increased the 
expression of COX-2/Ptgs2 while in the study of Lowe et al. 
(2007) ketamine treatment reduced the expression of this 
gene [49, 60]. Since the two studies were published simulta-
neously, this discrepancy was not discussed by the authors. 
The use of different conditions (3 mg/kg MK-801 prior to 
IPC, followed by lethal ischemia after 72 hours versus a sin-
gle i.p. injection of 80 mg/kg ketamine) may explain the dis-
crepancy. In another study, the influences of MK-801 and 
the uncompetitive NMDA receptor antagonist memantine (1-
amino-3, 5-dimethyladamantane) on brain mRNA expression 
were compared [61]. Male adult Wistar rats were i.p. in-
jected with 5-50 mg/kg memantine or 1 mg/kg MK-801 and 
the posterior cingulate and anterior retrosplenial cortices 
were dissected for RNA isolation. Microarray analyses (1090 
genes) revealed that 34 genes were regulated by the MK-801 
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the memantine treatment. Of these, 13 genes were regulated 
by both treatments, including nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, alpha 
(Nfkbia),  neurotrophic tyrosine kinase, receptor, type 2 
(Trk2), heat shock protein 4 (Hspa4/Hsp70), heat shock pro-
tein 5 (Hspa5/GRP78), GDP dissociation inhibitor 1 (Gdi1), 
hippocalcin-like 4 (Hpcal4/NVP-2),  glutamate receptor, 
ionotropic, N-methyl D-aspartate 2B (Grin2b/NMDAR2B), 
Neuromedin B transporter  (Nmbr),  neuropeptide Y (Npy), 
corticotropin releasing hormone (Crh/CRF), Na
+/K
+ trans-
porting ATPase 2 ( Atp1b2), Ca
2+ transporting ATPase-
isoform 2 (Atp2b2) and protein phosphatase 2 (formerly 2A), 
catalytic subunit, beta isoform (Ppp2cb) [61]. In a related 
study, male Wistar rats were repeatedly i.p. injected with 
0.13 mg/kg MK-801 once daily for 14 days. Gene expression 
in the bilateral amygdalae was analysed with a Rat Expres-
sion Array 230A Array spotted with 15923 probe sets (Af-
fymetrix). Twenty-three genes were downregulated and six-
teen genes were upregulated of which arginine vasopressin 
(Avp), prostaglandin D2 synthase (Ptgds), myelin-associated 
oligodendrocyte basic protein (Mobp; all downregulated) and 
insulin-like growth factor binding protein 2 (Igfbp2), soma-
tostatin receptor 2 (Sstr2), ectonucleotide pyrophospha-
tase/phosphodiesterase 2 (Enpp2) and Ttr (upregulated) were 
confirmed by qPCR [62]. In the four studies applying MK-
801 treatment [59-62], four different sets of affected genes 
have been identified, presumably due to the differences in 
the use of animals, injection methods, brain tissues and ar-
rays. The significance of these four gene sets remains to be 
established. 
  The most common hypothesis concerning the aetiology 
of schizophrenia is the dopaminergic hypothesis which was 
built on the finding that the clinical effectiveness of antipsy-
chotic drugs is related to their affinity for DA receptors. 
Since then advances in neurochemical imaging and a further 
understanding of the genetic aetiology of schizophrenia have 
led to the hypothesis that multiple (genetic, environmental) 
factors interact, resulting in DA dysregulation in schizophre-
nia patients [63]. It is therefore not surprising that DA recep-
tor agonists are useful in creating animal models to explore 
this hypothesis. An example of a DA receptor agonist is 
apomorphine [64]. Apomorphine-susceptible rats (so-called 
APO-SUS rats) constitute a model for schizophrenia. These 
rats have been pharmacogenetically selected based on their 
susceptibility for apomorphine as measured by their gnawing 
behaviour (>500 gnawing counts in 45 minutes). Extensive 
characterization of the APO-SUS rats and their phenotypic 
counterparts apomorphine-unsusceptible (APO-UNSUS) rats 
has shown that both genetic and environmental factors influ-
ence the complex phenotype of these rats [65]. Microarray 
analysis of hippocampal mRNA using Rat NeuroGEM 2.02 
microarrays containing 8478 Sprague Dawley rat nervous 
system cDNAs revealed that only one gene was differentially 
expressed between the two rat lines, namely Aph-1b. Further 
analysis showed that the expression difference of this -
secretase component was caused by a gene-dosage imbal-
ance, namely one or two copies of Aph-1b in APO-SUS rats 
and three copies in APO-UNSUS rats [40]. 
  Pharmacological models can also be generated by the 
treatment of animals with schizophrenia drugs such as olan-
zapine or clozapine [66]. Olanzapine is a second-generation 
antipsychotic agent that exhibits greater 5HT2A than D2 
receptor antagonism and has high affinity for a number of 
other receptors, such as muscarinic, 1-adrenergic, hista-
mine-H1, 5HT2A, 5HT2C, 5HT1A, 5HT6, 5HT7, and 5HT3 
receptors [67]. Additionally, olanzapine facilitates NMDA 
neurotransmission  via its effects on glutamatergic NMDA 
and AMPA receptors [68]. To study the influence of chronic 
olanzapine treatment, adult male Sprague–Dawley albino 
rats were administered daily for 21 days with 1 ml olanzap-
ine (2 mg/kg/day, i.p.) and sacrificed 24 h after the last injec-
tion under deep anaesthesia. Gene expression in the frontal 
cortex was analysed using an Affymetrix rat genome 230 2.0 
array set. The results showed downregulation of 31 genes 
and upregulation of 38 genes in the drug-treated versus con-
trol brains. The application of real-time qPCR verified the 
magnitude and direction of the changes for a number of sig-
nificantly affected genes, including calbindin 3 (S100g), 
reelin,  RGS2, and insulin 2 [69]. Recently, Duncan et al. 
(2008) compared the effects of the conventional antipsy-
chotic drug haloperidol on gene expression with the effects 
of the atypical drugs olanzapine and clozapine [70]. Halop-
eridol (1 mg/kg), olanzapine (10 mg/kg), or clozapine (10 
mg/kg) was administered via daily i.p. injection for 7 days to 
male C57BL/6 mice. Five hours after the last injection, the 
mice were sacrificed under 4% halothane anaesthesia. 
Whole-brain gene expression profiles were analysed using 
the Affymetrix GeneChip Mouse Genome 430 2.0 microar-
rays. Data analysis revealed that ~12,000 out of over 39,000 
transcripts showed > 1.5-fold change by at least one drug 
compared with saline-treated controls and 249 transcripts 
were coregulated by all three antipsychotic drugs. Twenty 
candidate genes were chosen for further expression analysis 
based on their regulation by multiple drugs, the chromoso-
mal location of their human orthologs, pattern of expression, 
or relevant neurobiological function [70]. Some of these 
genes have been genetically associated with schizophrenia, 
namely neuroplastin  (Nptn/Sdfr1), numb homolog (Droso-
phila)-like (Numbl),  proteolipid protein 1 (Plp1),  gamma-
aminobutyric acid (GABA) A receptor, 1 (Gabra1),  and 
reticulon 4 (Rtn4/(NogoA)  [71-75]. Thirteen out of the 
twenty genes showed a statistically significant change in 
mRNA expression as determined by qPCR. To examine 
whether the changes in mRNA expression had led to changes 
into protein expression, whole-brain expression of three of 
the proteins was analysed with Western blots. The Kv chan-
nel interacting protein 3 (Kcnip3) was downregulated in 
brain tissues of the haloperidol- and olanzapine-treated rats, 
Kv1.1 was upregulated in the haloperidol-treated rats and 
NEDD4 was downregulated in the olanzapine-treated rats. 
The authors hypothesised that the specific effects of multiple 
antipsychotic drugs on the expression of four genes regulat-
ing voltage-gated ion channels –potassium voltage-gated 
channel, Shaker-related subfamily, member 1 (Kcna1), Po-
tassium voltage-gated channel, Shaker-related subfamily, 
beta member 1 (Kcnab1), Kcnip3 and Neural precursor cell 
expressed, developmentally downregulated gene 4 (Nedd4)– 
may indicate a role for these neuronal regulators in antipsy-
chotic drug action [70]. In another study on clozapine-treated 
rats, no genes encoding a potassium voltage-gated ion chan-
nel have been found to be deregulated [76]. Male Wistar rats 388    Current Neuropharmacology, 2010, Vol. 8, No. 4  van Schijndel and Martens 
(~200 g) were given a single clozapine (25 mg/kg) i.p. injec-
tion and sacrificed 1, 6 or 24 hrs after the drug administra-
tion. Gene expression in the prefrontal and anterior cingulate 
cortices was analyzed with an Atlas Rat 1.2 Array filter 
(Clontech) of 1176 sequence-verified cDNAs. In situ hy-
bridization was used to validate the regulation of 35 genes 
with the most pronounced changes in the filter array experi-
ments or their close functional relatives. These genes belong 
to many different functional classes. A modest but consistent 
increase (~15%) of chromogranin A (Chga) mRNA was   
observed in the outer and inner layers of the prefrontal   
cortex at 6 hrs after a single clozapine injection. Twenty four 
hrs after clozapine treatment synaptotagmin V mRNA was 
downregulated in the inner layers of the frontal cortex 
(~30%), and in the outer and inner layers of the parietal   
cortex (~15–20%). These results were consistent with the 
filter array results. In situ hybridization confirmed the 
upregulation (~20%) of calcineurin A mRNA in the inner 
layers of the infralimbic cortex 6 hrs after clozapine treat-
ment and a more pronounced upregulation (~70%) in the 
inner layers of the frontal cortex 24 hrs after the treatment. 
Following a chronic treatment (daily injection for 17 days) 
with haloperidol or clozapine, six of the 35 genes were dif-
ferentially expressed as shown by in situ hybridization. The 
chronic clozapine treatment changed the expression of Chga, 
Son of sevenless (Sos) and Syntaxin binding protein 1 
(Stxbp1/Sec1)  [76]. An effect of such chronic clozapine 
treatment has been reported previously for Chga mRNA   
expression in striatum, nucleus accumbens, dorsal raphe   
nucleus and prefrontal cortex [77, 78]. The expression of 
Inhibitor of DNA-binding 2 (Id2), RAB12, member RAS 
oncogene family (Rab12)  and Visinin-like protein 2 was 
changed by chronic treatment with haloperidol. Interestingly, 
yisinin-like protein 1 has been found previously to be   
downregulated 1 and 24 hrs after a single PCP injection   
(8 mg/kg) in the entorhinal cortex and nucleus accumbens of 
male Sprague-Dawley rats, respectively [79]. Investigators 
who studied previously the effect of PCP on gene expression 
in mice [45] also studied gene expression in male Institute  
of Cancer Research mice (Charles River Laboratories)   
that received daily subcutaneous injections of clozapine   
(7.5 mg/kg) for 20 days. Mice were sacrificed 20 hrs   
after the last injection and mRNA expression in the cerebral 
cortical tissues was analysed with a Clontech Atlas Mouse 
1.2 Array membrane. Of the 1176 genes on this membrane, 
the expression of potassium channel Kcnab1 and prostaglan-
din D2 synthase was decreased, while the expression of sero-
tonin receptor type 2 and myelin-associated oligodendrocytic 
basic protein was increased [80]. In a more recent study, the 
chronic effects of haloperidol, clozapine and phenylpropano-
lamine (an anorexiant drug used to encourage weight   
loss) on 10-12 week old male C57BL6 mice were examined 
[81]. Mice were administered with the drugs orally via food  
pellets daily for 31 days and gene expression in the cortices 
was analysed using the Murine Genome U74A Array   
(Affymetrix) containing ~12000 genes. The authors focused 
on differentially expressed genes involved in body weight 
regulation since antipsychotic drugs such as clozapine   
are associated with clinically significant weight gain [82]. 
However, although the mice treated with clozapine had the 
highest food intake they weighed significantly less than the 
control mice, presumably because the induced weight gain in 
rodents treated with antipsychotic drugs is influenced by a 
variety of factors [83]. The genes aldolase 3 (Aldo3) and 
phospholipase C beta 1 (Plcb1), involved in glycolysis and 
lipid metabolism, respectively, were differentially expressed 
in the clozapine-treated but not in the haloperidol-treated 
mice [81], suggesting that these genes are involved in the 
regulation of body weight rather than in schizophrenia.   
Although drugs such as haloperidol and the atypical antipsy-
chotic risperidone may have different receptor affinities, they 
interfere with neural plasticity and signal transduction in a 
similar manner [84]. Adult Sprague-Dawley rats were daily 
injected i.p. with haloperidol or risperidone and following 
acute or chronic (4 weeks) treatment gene expression in   
the prefrontal/fronto-parieto-temporal cortices was analysed 
with arrays containing 8000 rat genes. The acute treatment 
with risperidone affected the expression of more genes than 
the acute haloperidol treatment (89 and 28 genes, respec-
tively). This could be due to the fact that the high-potential 
D2-, 5HT2- and NA-antagonist risperidone binds to diverse 
receptors, while haloperidol acts only as a D2-antagonist. Of 
the 28 genes differentially expressed upon haloperidol treat-
ment, 18 were also differentially expressed following 
risperidone treatment. In general, each of the drugs affected 
genes with specific functions in signal transduction, tran-
scriptional and translational regulation, protein turnover, and 
cellular metabolism [84]. The effect of chronic risperidone 
treatment of rats on mRNA expression levels in the frontal 
cortex was also studied by Chen and Chen [85]. The use of 
GeneMap Rat Clone Arrays containing cDNA fragments of 
1536 genes revealed 17 genes to be differentially expressed, 
eight of which were validated by qPCR. None of these eight 
genes were found to be differentially expressed in the acute 
and chronic risperidone study of Fehér et al. [84]. 
mRNA EXPRESSION PROFILING IN GENETIC 
ANIMAL MODELS 
  In most cases, a genetic animal model for schizophrenia 
carries a mutation in a gene involved in brain development 
[86]. The mutation is usually in a dopaminergic or a gluta-
matergic gene, in line with the use of DA agonists and 
NMDA antagonists in pharmacological models for schizo-
phrenia [87]. Examples of dopaminergic and glutamatergic 
mutant animals include the DA transporter (DAT), Nurr1 and 
glutamate receptor, ionotropic, NMDA2A (Grin2a/NR2A) 
knockout (KO) mice, and glutamate receptor, ionotropic, 
NMDA1 (Grin1/NR1) knock down mice [88-90]. To our 
knowledge, gene expression has not been analyzed in any of 
these nor in other dopaminergic or glutamatergic mutant 
mice, except in the Nurr1 KO mice. Nurr1, an orphan mem-
ber of the steroid/thyroid hormone receptor family, is an ab-
solute requirement for the proper development of midbrain 
DA neurons. Homozygous Nurr1 KO mice fail to generate 
midbrain DA neurons, are hypoactive and die soon after 
birth [91]. Gene expression has been analyzed in the ventral 
midbrain of homozygous Nurr1 KO mice at embryonic day 
12.5 and PND0 using Affymetrix MGU74Av2 and 
MGU74Bv2 gene chips. Among the differentially expressed 
genes were DA-related genes such as tyrosine hydroxylase 
(TH) and DAT, and also guanosine 5’-triphospate (GTP) 
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zyme in the synthesis of tetrahydrobiopterin (BH4), a cofac-
tor essential for TH [92]. 
  Genetic animal models have also been developed on the 
basis of genes thought to play an important role in the aetiol-
ogy of schizophrenia. One of such genes is Reelin (RELN) 
[93-95] and therefore the heterozygous reeler mouse, with a 
reelin insufficiency, has become of interest as an animal 
model [96]. In the reeler mouse brain, the expression of the 
mouse homologue of Strawberry Notch (Sno) was reduced. 
In vitro assays have shown that reelin treatment indeed en-
hanced the expression of Sno. Being a component of the 
notch signaling pathway in Drosophila [97], Sno thus links 
the reelin signal to the regulation of neurogenesis [98]. A 
further schizophrenia animal model is represented by the 
Df1/+ mouse because it carries a hemizygous deletion from 
Es2 to Ufd1l (referred to as Df1 [99]), a region syntenic with 
a human 22q11 deletion causing DiGeorge syndrome; 35% 
of the DiGeorge syndrome patients develop schizophrenia 
[100]. In hippocampal dentate granule neurons of 10-week-
old Df1/+ mice, two genes with a ribosomal protein function 
(Rps2 and Arbp) have been found to be upregulated. Eleven 
genes were downregulated, ten of which were located in the 
22q11 region, including the gene encoding COMT. The only 
downregulated gene not located in the deleted region was B-
cell CLL/lymphoma 7a (Bcl7a), a gene with an unknown 
function [100]. Other genetic animal models for schizophre-
nia concern mice lacking the protein kinase C interacting 
protein/histidine triad nucleotide binding protein 1 (PKCI/ 
HINT1) [101, 102], brain-derived neurotrophic factor (BDNF) 
[103-105], neural cell adhesion molecule (Ncam) 180 [106], 
cyclin-dependent kinase 5 (Cdk5) [107], neural PAS domain 
protein 3 (NPAS3) [108] or LIM homeobox protein 5 (Lhx5) 
[109], mice carrying a mutation in proline dehydrogenase 2 
(PRODH2) [110], Disrupted-in-Schizophrenia-1 (DISC1) 
[111, 112] or neuregulin-1 [113] as well as the Chakragati 
(Ckr) mouse [114]. No gene expression analyses have been 
performed on any of these genetic animal models. 
CONCLUSIONS AND FUTURE DIRECTIONS 
  Our overview of the microarray analyses performed in 
animal models for schizophrenia illustrates that we still can 
not provide a conclusive answer to the question which genes 
play a role in the aetiology of this complex disorder. The 
numerous mRNA expression studies have resulted in even 
more genes that could play a role in the onset of schizophre-
nia than was previously thought. However, since most of 
these genes have been found in only a single study, their 
significance is at present unclear. An exception may consti-
tute the family of sodium and potassium voltage-gated chan-
nels that seems of interest as in seven out of the twenty-six 
microarray studies discussed here at least one member of this 
family has been found to be differentially expressed [34, 45, 
46, 61, 69, 70, 80]. Intriguingly, genes encoding potassium 
channels have already been implicated in the aetiology of 
schizophrenia, such as KCNN3 [115] and recently KCNH2 
[116]. In particular KCNH2 appears to be a strong contribu-
tor to the schizophrenia phenotype because of the presence 
of disease-associated SNPs in its gene together with compel-
ling, converging evidence from (functional) brain imaging, 
mRNA expression and electrophysiological studies [117]. 
  The neurodevelopmental, pharmacological and genetic 
animal models for schizophrenia have been created in differ-
ent ways. This circumstance may explain the near lack of 
overlap between the genes found to be differentially ex-
pressed in the various animal models. Moreover, heterogene-
ity such as the ages of the animals and the ways of treating or 
sacrificing the animals occurs even within one group of ani-
mal models (either neurodevelopmental, pharmacological or 
genetic). For instance, in the various studies on the pharma-
cological models the animals were treated differently in that 
substances were administered at different concentrations and 
at different time intervals, and the time points at which the 
animals were sacrificed following drug administration were 
not the same. Furthermore, before being sacrificed in some 
of these studies the animals were anaesthetized, while it is 
known that anaesthesia may well affect gene expression   
levels [118-121]. In addition, the methods of dissecting the 
brain areas differed and a number of brain regions were ana-
lysed, with each region having its specific mRNA expression 
pattern. For the gene expression analyses, a variety of mi-
croarrays and platforms have been used, ranging in their 
coverage from a couple of thousand genes to the nearly 
complete genome. The variation among the various experi-
ments was further increased by the use of different statistical 
methods and cut-off values. The studies performed with the 
early microarrays and dealing with only a limited number of 
genes should therefore be repeated with the newest microar-
rays or deep sequencing approaches and using the latest 
knowledge, e.g. regarding the effect of anaesthesia on gene 
expression. More overlap in the results of the future genome-
wide mRNA expression studies may then occur, possibly 
leading to the identification of common molecular pathways 
that may well play a role in the aetiology of schizophrenia. 
At present however the studies performed thus far do not 
provide decisive insights. Clearly, more molecular analyses 
of the various animal models for schizophrenia are neces-
sary. It would be of interest to include in such studies   
new genome-wide technologies to explore, besides mRNA 
expression profiles, epigenetic (e.g. DNA methylation or 
histone acetylation), and noncoding RNA and (phospho) 
protein expression patterns as well. 
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